All studies involving SM/J


Filter by:
Data set Procedure What's in this data set Panel Sex Age (weeks) Year
Ackert1 body size and weight Body weight, body length, body mass index. Aging study, 6mo, 12mo, 20mo. inbred   (32) both 26, 52, 87 wks 2008
Ackert1 DXA Body mass, fat mass, lean mass, bone mineral density and content, body area, bone area. Aging study, 6mo, 12mo, 20mo. inbred   (32) both 26, 52, 87 wks 2008
Albers1 lipid profile
with high-fat diet
Cholesterol, HDL, non-HDL, triglycerides, phospholipids. 4h fast, plasma. Baseline vs. high-fat diet (6wks). inbred   (15) both 6-14wks 1999
Albers1 protein activity assessment
with high-fat diet
Phospholipid transfer protein activity. 4h fast. inbred   (15) both 6-14wks 1999
Benavides1 genotype assessment Gpr84 allele assessment. PCR, sequencing. inbred w/CC8   (58) both 6wks 2013
Benoist1 immune cell quantification Regulatory T cells (Treg), thymus, spleen. inbred   (33) m 5-6wks 2007
Berndt1 ventilator
with methacholine
Airway resistance. Baseline vs. methacholine-challenged (several doses). inbred   (37) both 9-12wks 2010
Berndt2 plethysmography
with methacholine
Lung, respiratory function. Baseline vs. methacholine-challenged (several doses). inbred   (29) both 9-12wks 2010
Berndt2 ventilator
with methacholine
Lung, respiratory function. Anesthetized forced oscillation. Baseline vs. methacholine-challenged (several doses). inbred   (29) both 9-12wks 2010
Berndt4 histopathology Lung adenoma frequency and severity at 20mo. Tumor incidence, cancer, aging. inbred   (28) both 87wks 2011
Boon1 body weight
with influenza A (H5N1) virus
Influenza A (H5N1) virus (several doses) vs. baseline. inbred   (23) f 6-9wks 2011
Boon1 health assessment
with influenza A (H5N1) virus
Survival rate, influenza A (H5N1) virus (several doses). Strain H5N1 susceptibility score. inbred   (23) f 6-9wks 2011
Bopp1 health assessment
with Plasmodium berghei
Susceptibility, Plasmodium berghei (malaria). Parasitemia in blood and distribution in brain, spleen, lungs, liver. inbred   (31) both 8-12wks 2010
Broad2 genotyping SNP profiling, 131,000+ genomic locations, 1-19,X. inbred   (89) 2009
Brown1 body weight Body weight inbred   (14) both 10wks 2004
Brown1 elevated plus maze Locomotor, exploratory, and anxiety-related behavior. inbred   (14) both 10wks 2004
Brown1 elevated zero maze Locomotor, exploratory, and anxiety-related behavior. inbred   (14) both 10wks 2004
Brown1 light-dark box Anxiety, avoidance behavior. inbred   (14) both 10wks 2004
Brown1 open field test Locomotor, exploratory, and anxiety-related behavior. inbred   (14) both 10wks 2004
Brown2 Barnes circular maze Spatial learning and memory. inbred   (14) both 10-18wks 2004
Brown2 Morris water maze Spatial learning and memory. inbred   (14) both 10-18wks 2004
Brown2 olfactory discrimination task Olfactory-related learning and memory. inbred   (14) both 10-18wks 2004
Brown2 rotarod Latency to fall from accelerating rotarod. 7 day trials. inbred   (14) both 10-18wks 2004
Brown2 visual water box Spatial learning and memory. inbred   (14) both 10-18wks 2004
Brugnara1 complete blood count Hematology. inbred   (10) both 8wks 2013
Brugnara1 ion transport assessment Hematology red cell ion content, ion transport. inbred   (10) both 8wks 2013
CGD-MDA1 genotyping SNP profiling, 470,000+ genomic locations, 1-19,X,Y,MT. inbred   (142) m 2014
CGDpheno1 body size and weight Body weight and length. inbred w/CC8   (72) both 10-13wks 2009
CGDpheno1 complete blood count Hematology. inbred w/CC8   (72) both 10-13wks 2009
CGDpheno1 DXA Body mass, fat mass, lean mass, bone mineral density. inbred w/CC8   (72) both 10-13wks 2009
CGDpheno1 lipid profile Cholesterol, HDL, triglycerides, free fatty acids. 4h fast, plasma. inbred w/CC8   (72) both 10-13wks 2009
CGDpheno1 metabolic panel Clinical blood chemistry (plasma). 4h fast. inbred w/CC8   (72) both 10-13wks 2009
Chen1 immune cell quantification Natural killer T cells in peripheral blood, spleen, thymus. inbred   (38) both 8-10wks 2011
Cheverud1 body weight
with high-fat diet
Body weight and growth curve from age 1wk to 22wks (pre-wean, post-wean, adult). High-fat diet (17wks) vs. control. LGXSM w/par   (19) both 12-16wks 2004
Cheverud1 fat pad weights
with high-fat diet
High-fat diet (17wks) vs. control. LGXSM w/par   (19) both 12-16wks 2004
Cheverud1 glucose tolerance
with high-fat diet
High-fat diet (17wks) vs. control. 0 to 120 min after 10% glucose i.p. 4h fast. LGXSM w/par   (19) both 12-16wks 2004
Cheverud1 hormone quantification
with high-fat diet
Insulin, leptin. LGXSM w/par   (19) both 12-16wks 2004
Cheverud1 lipid profile
with high-fat diet
Cholesterol, triglycerides, free fatty acids. High-fat diet (17wks) vs. control. 4h fast, serum. LGXSM w/par   (19) both 12-16wks 2004
Cheverud1 organ weights
with high-fat diet
Heart, liver, kidney, spleen weights after high-fat diet (17wks) vs. control. LGXSM w/par   (19) both 12-16wks 2004
Crabbe3 body weight
with ethanol
Body weight inbred   (22) both 9-17wks 2003
Crabbe3 rotarod
with ethanol
Baseline and ethanol i.p. 3 fixed speeds (several doses) and accelerating. inbred   (22) both 9-17wks 2003
Crabbe4 alcohol quantification
with ethanol
Blood alcohol concentration after ethanol 2 g/kg i.p., several timepoints. inbred   (21) both 9-17wks 2003
Crabbe4 dowel balance test
with ethanol
Latency to fall 0 min and 30 min post-injection, 2 widths. Ethanol 2 g/kg. inbred   (21) both 9-17wks 2003
Crabbe4 grip strength
with ethanol
Baseline vs. 30 min after ethanol 2 g/kg i.p. inbred   (21) both 9-17wks 2003
Crabbe4 vertical wire mesh
with ethanol
Latency to fall 30 min post-injection. Ethanol 2 g/kg i.p. inbred   (21) both 9-17wks 2003
Crowley1 behavior observation
with haloperidol
Observed involuntary repetitive movement. Baseline vs. during and after haloperidol 60d implant (several timepoints). inbred w/CC8   (27) m 9-28wks 2012
Crowley1 body weight
with haloperidol
Baseline vs. after haloperidol 60d implant. inbred w/CC8   (27) m 9-28wks 2012
Crowley1 drug and metabolite quantification
with haloperidol
Haloperidol concentration (plasma). Baseline vs. during and after haloperidol 60d implant (several timepoints). inbred w/CC8   (27) m 9-28wks 2012
Crowley1 inclined screen test
with haloperidol
Baseline vs. during and after haloperidol 60d implant (several timepoints). inbred w/CC8   (27) m 9-28wks 2012
Crowley1 open field test
with haloperidol
Locomotor activity, exploratory behavior, involuntary movement. Baseline vs. haloperidol 60d implant (several timepoints). 60 min test. inbred w/CC8   (27) m 9-28wks 2012
Dietrich1 in vitro assay
with Bacillus anthracis lethal toxin
Bacillus anthracis lethal toxin (anthrax) susceptibility. inbred   (50) f 6-8wks* 1998
DiPetrillo1 urinalysis Microalbumin, creatinine, ratio. inbred w/CC7   (34) m 10wks 2012
Donahue1 DXA Body mass, fat mass, lean mass, bone mineral density and content, craniofacial dimensions. inbred w/CC7   (30) both 15-16wks 2002
Donahue1 hormone quantification Osteocalcin, insulin-like growth factor 1. inbred w/CC7   (30) both 15-16wks 2002
Donahue1 metabolic panel Thyroxine (serum). inbred w/CC7   (30) both 15-16wks 2002
Finn1 bottle choice test
with ethanol
Voluntary consumption of ethanol, and ethanol with saccharin (several doses in water). inbred   (22) both 8-12wks 2007
Geuther1 open field test Distance traveled, after first 10 min and after 55 min. other   (58) both 7-26wks 2019
Graubert1 complete blood count
with ENU
Hematology. inbred   (20) both 9wks; 12-64wks 2006
Graubert1 histopathology
with ENU
Tumor growth frequency rates. ENU mutagen 100 mg/kg vs. control. inbred   (20) both 9wks; 12-64wks 2006
Gros1 genotype assessment
with Candida albicans
C5 allele sufficiency or deficiency. inbred   (36) f 8-12wks 2011
Gros1 in vitro assay
with Candida albicans
Susceptibility to infection with Candida albicans. inbred   (36) f 8-12wks 2011
Gros2 health assessment
with Plasmodium chabaudi
Survival score and susceptibility, Plasmodium chabaudi. inbred   (25) both 8-10wks 2012
Gros2 microscopy
with Plasmodium chabaudi
Percent of Plasmodium chabaudi-infected erythrocytes in blood. inbred   (25) both 8-10wks 2012
Gupta1 body weight Body weight of newborns. inbred   (8) both postnatal 2011
Gupta1 organ dimensions Kidney morphology of newborns. Planar surface area. inbred   (8) both postnatal 2011
Gupta1 organ weights Kidney weight of newborns. inbred   (8) both postnatal 2011
Gupta1 renal function assay Vesico-ureteric reflux in newborns. Kidney function. inbred   (8) both postnatal 2011
Hadsell1 body weight Daily body weight gain of cross-fostered pups. inbred   (31) f 14-18wks 2012
Hadsell1 colony observation Maternal nurturing study. inbred   (31) f 14-18wks 2012
Hadsell2 mineral quantification concentrations of various minerals in milk inbred   (31) f 14-20wks 2018
Harrill1 body weight
with isoniazid
Body weight. Isoniazid-treated vs. control. inbred   (34) f 8-10wks 2011
Harrill1 histopathology
with isoniazid
Liver pathology scores. Isoniazid-treated vs. control. inbred   (34) f 8-10wks 2011
Harrill1 lipid profile
with isoniazid
Cholesterol, triglycerides. Hepatic lipids. Isoniazid-treated vs. control. inbred   (34) f 8-10wks 2011
Harrill1 metabolic panel
with isoniazid
Alanine transaminase. Isoniazid-treated vs. control. inbred   (34) f 8-10wks 2011
Harrill1 organ weights
with isoniazid
Body, liver, kidney weights. Isoniazid-treated vs. control. inbred   (34) f 8-10wks 2011
Harrill2 biomarker quantification
with DB289
Kidney injury molecule 1 (KIM-1). DB289-treated vs. control. inbred   (34) f 6-8wks 2012
Harrill2 body weight
with DB289
DB289-treated vs. control. inbred   (34) f 6-8wks 2012
Harrill2 drug and metabolite quantification
with DB289
Kidney metabolite (DB75) concentration. DB289-treated vs. control. inbred   (34) f 6-8wks 2012
Harrill2 metabolic panel
with DB289
Blood urea nitrogen, alanine transaminase, creatinine. DB289-treated vs. control. inbred   (34) f 6-8wks 2012
Harrill2 organ weights
with DB289
Kidney and liver weights. DB289-treated vs. control. inbred   (34) f 6-8wks 2012
Harrill2 urinalysis
with DB289
Urine volume, creatinine. DB289-treated vs. control. inbred   (34) f 6-8wks 2012
Haston1 bronchoalveolar lavage assessment
with radiation
Bronchoalveolar cell differential after exposure to radiation (18 Gy). inbred   (26) both 15-36wks 2012
Haston1 health assessment
with radiation
Survival rate and health assessment after exposure to radiation. Number of days without respiratory distress (max 26 wks). inbred   (26) both 15-36wks 2012
Haston1 histopathology
with radiation
Post exposure to radiation. inbred   (26) both 15-36wks 2012
Hawes1 ophthalmoscopy Retinal fundoscopic examination. inbred w/CC7   (41) both 6-7wks 2008
Hawes1 slit lamp Eye morphology. Frequency rates of disorders. inbred w/CC7   (41) both 6-7wks 2008
Hillebrands1 histopathology Kidney pathology at 20mo. inbred   (23) both 87wks 2014
HMDPpheno1 DXA Bone mineral density (whole body, femur, spine). HMDP   (96) m 16wks 2011
HMDPpheno10 metabolite quantification Liver metabolic profiling. Molecular measures of nucleotides, peptides. 16h fast. HMDP   (106) m 16wks 2014
HMDPpheno2 lipid profile Cholesterol, HDL, non-HDL, triglycerides, free fatty acids. 16h fast, plasma. HMDP   (99) m 16wks 2010
HMDPpheno2 NMR Percent fat. HMDP   (99) m 16wks 2010
HMDPpheno3 tail cuff Heart rate and blood pressure. Conscious mice. HMDP   (58) m 9-10wks 2012
HMDPpheno4 fear conditioning test Contextual fear, cued fear. HMDP   (94) m 10wks 2011
HMDPpheno5 complete blood count Hematology. HMDP   (83) m 16wks 2013
HMDPpheno6 metabolite quantification Liver metabolic profiling. Molecular measures of amino acids. 16h fast. HMDP   (106) m 16wks 2014
HMDPpheno7 metabolite quantification Liver metabolic profiling. Molecular measures of carbs, cofactors, vitamins, energy, xenobiotics. 16h fast. HMDP   (106) m 16wks 2014
HMDPpheno8 metabolite quantification Liver metabolic profiling. Molecular measures of lipids (non-lysolipids). 16h fast. HMDP   (106) m 16wks 2014
HMDPpheno9 metabolite quantification Liver metabolic profiling. Molecular measures of lipids (lysolipids). 16h fast. HMDP   (106) m 16wks 2014
Jax2 MHC haplotype tissue typing Major histocompatibility complex (MHC) H2 haplotype. inbred   (56) both 2000
Jax3 colony observation Reproductive performance. inbred   (33) f various 1991
Jax4 colony observation Appearance, coat color inbred   (61) both 2006
Jax5 colony observation Reproductive performance. inbred   (35) f various 2009
Korstanje1 urinalysis Microalbumin, creatinine, ratio. Aging study, 6mo, 12mo, and 20mo. inbred   (30) both 52, 78, 104 wks 2008
Korstanje2 histopathology Kidney pathology. Aging study, 6mo, 12mo, 20mo. inbred   (29) m 52, 78, 104 wks 2013
Lightfoot1 body weight Body weight inbred   (41) both 8-9wks 2010
Lightfoot1 running wheel monitoring Distance, duration, speed. inbred   (41) both 8-9wks 2010
Massett1 body weight Body weight inbred   (34) both 8wks 2012
Massett1 treadmill endurance test Duration, distance, work. inbred   (34) both 8wks 2012
Maurer1 body weight
with atenolol, isoproterenol
Isoproterenol or atenolol vs. control. inbred   (23) m 10-12wks 2009
Maurer1 ECG
with atenolol, isoproterenol
Heart rate and wave amplitudes and intervals. Unconscious. Isoproterenol or atenolol vs. control. inbred   (23) m 10-12wks 2009
Maurer1 organ weights
with atenolol, isoproterenol
Heart, atria, ventricle weights. Isoproterenol or atenolol vs. control. inbred   (23) m 10-12wks 2009
Maurer1 tail cuff
with atenolol, isoproterenol
Heart rate and blood pressure. Conscious mice. Isoproterenol or atenolol vs. control. inbred   (23) m 10-12wks 2009
Mills1 apoptosis assessment Aging study, 6mo, 12mo, 20mo. inbred   (30) both 26, 52, 87 wks 2008
Mills1 chromosome instability assessment Chromosome instability. Aging study, 6mo, 12mo, 20mo. inbred   (30) both 26, 52, 87 wks 2008
Mogil1 nociception assay Battery of tests for mechanical, chemical, thermal nociception. inbred   (12) m 6-18wks 2002
Mogil2 monitoring system Locomotor activity. Light and dark phases. inbred   (12) m 6-10wks 2000
Mogil3 nociception assay von Frey nociception test, baseline and after spared nerve injury (SNI) surgery as a hypersensitizer. inbred   (18) both 7-12wks 2012
Naggert1 body weight
with high-fat diet
High-fat diet for 8wks. inbred w/CC7   (43) both 5, 21 wks 2003
Naggert1 DXA
with high-fat diet
Body mass, fat mass, lean mass, bone mineral density and content after 8wks on high-fat diet. inbred w/CC7   (43) both 5, 21 wks 2003
Naggert1 hormone quantification
with high-fat diet
Insulin and leptin after 18wks on high-fat diet. Multiple readings per animal were averaged. inbred w/CC7   (43) both 5, 21 wks 2003
Naggert1 metabolic panel
with high-fat diet
Glucose (plasma). Baseline vs. high-fat diet (17wks). 4h fast. inbred w/CC7   (43) both 5, 21 wks 2003
Paigen1 body weight
with high-fat diet
Baseline vs. high-fat diet for 8wks. inbred   (44) both 15-19wks 2000
Paigen1 histopathology
with high-fat diet
Gallstone, gallbladder, and atherosclerosis lesion histopathology after 8wks on high-fat diet. inbred   (44) both 15-19wks 2000
Paigen1 lipid profile
with high-fat diet
Cholesterol, HDL, non-HDL. 4h fast, plasma. Hepatic lipids. 8wks on high-fat diet. inbred   (44) both 15-19wks 2000
Paigen1 metabolic panel
with high-fat diet
Alanine transaminase, bile salts (plasma) after 8wks on high-fat diet. 4h fast. inbred   (44) both 15-19wks 2000
Paigen1 organ dimensions
with high-fat diet
Gallbladder volume after 8wks on high-fat diet. inbred   (44) both 15-19wks 2000
Paigen1 organ weights
with high-fat diet
Liver weight after 8wks on high-fat diet. inbred   (44) both 15-19wks 2000
Paigen2 histopathology
with high-fat diet
Aortic lesion size histopathology. Baseline vs. high-fat diet (17wks). inbred w/CC7   (43) both 7-9wks, 24-27wks 2002
Paigen2 lipid profile
with high-fat diet
Cholesterol, HDL, non-HDL, triglycerides. Baseline vs. high-fat diet (17wks). 4h fast, plasma. inbred w/CC7   (43) both 7-9wks, 24-27wks 2002
Paigen4 lipid profile Cholesterol, HDL, non-HDL, triglycerides. 4h fast, plasma. inbred w/CC7   (43) both 10wks 2002
Peters1 coagulation test Fibrinogen. inbred w/CC7   (43) both 10wks 2001
Peters1 complete blood count Hematology. inbred w/CC7   (43) both 10wks 2001
Peters4 complete blood count Hematology. Aging study, 6mo, 12mo, 18mo, 24mo. inbred   (30) both 26, 52, 78, 104 wks 2007
Petkova1 complete blood count Hematology. Aging study, 6mo, 12mo, 18mo, 24mo. inbred   (32) both 26, 52, 78, 104 wks 2007
Petkova1 immune cell quantification Aging study, 6mo, 12mo, 18mo, 24mo. inbred   (32) both 26, 52, 78, 104 wks 2007
Pletcher1 body weight Body weight inbred   (32) m 7-9wks 2007
Pletcher1 hormone quantification Corticosterone (serum). inbred   (32) m 7-9wks 2007
Pletcher1 open field test Locomotor and anxiety-related behavior. 10 min test. inbred   (32) m 7-9wks 2007
Pletcher1 tail suspension test Immobility percentage. inbred   (32) m 7-9wks 2007
Reed1 body size and weight Body weight, body length, body mass index. inbred   (28) m 8, 12 wks 2009
Reed1 fat pad weights Epididymal, retroperitoneal. inbred   (28) m 8, 12 wks 2009
Reed1 organ weights Heart, kidney weights. inbred   (28) m 8, 12 wks 2009
Rhodes1 body weight
with exercise
Exercise wheel group vs. control group. inbred   (12) both 8-15wks 2010
Rhodes1 microscopy
with exercise
Examination of hippocampus dentate gyrus. Exercise wheel group vs. control group. inbred   (12) both 8-15wks 2010
Rhodes1 running wheel monitoring
with exercise
Locomotor activity. Exercise wheel group vs. control group. Distance per day. inbred   (12) both 8-15wks 2010
Sandell1 health assessment Post-injury wound healing. Ear cartilage and articular cartilage. LGXSM w/par   (15) both 6-7wks 2012
Sandell1 histopathology Post-injury wound healing. Articular cartilage at 12wks and 16wks post-injury. LGXSM w/par   (15) both 6-7wks 2012
Seburn2 gait analysis Aging study, 6mo, 18mo. inbred   (32) both 26, 52, 78, 104 wks 2008
Seburn2 grip strength Peak tension. 3 trials. Aging study, 6mo, 12mo, 18mo, 24mo. inbred   (32) both 26, 52, 78, 104 wks 2008
Shockley1 body weight
with high-fat diet
High-fat diet for 4wks vs. control. inbred   (10) both 10-13wks 2008
Shockley1 lipid profile
with high-fat diet
Cholesterol, HDL, triglycerides, fatty acids. High-fat diet (4wks) vs. control. 5h fast, serum. inbred   (10) both 10-13wks 2008
Shockley1 metabolic panel
with high-fat diet
Clinical blood chemistry measures (serum). High-fat diet (4wks) vs. control. inbred   (10) both 10-13wks 2008
Tarantino1 body weight
with cocaine
Body weight inbred   (45) m 8-11wks 2015
Tarantino1 open field test
with cocaine
Locomotor activity. Baseline (saline) vs. cocaine 20 mg/kg i.p. 30 min test. inbred   (45) m 8-11wks 2015
Tarantino2 forced swim test
with ovariectomy
Mice with ovariectomy surgery vs. controls (sham surgery), 6 min test. inbred   (37) f 8-10wks 2016
Tarantino2 open field test
with ovariectomy
Locomotor activity and exploratory behavior. Mice with ovariectomy surgery vs. controls (sham surgery), 10 min test. inbred   (37) f 8-10wks 2016
Threadgill1 biomarker quantification
with acetaminophen
Liver cytochrome isoforms. Acetaminophen vs. control. 18h fast. inbred w/CC7   (37) m 8-17wks 2005
Threadgill1 histopathology
with acetaminophen
Liver histopathology, necrosis after acetaminophen vs. control. 18h fast. inbred w/CC7   (37) m 8-17wks 2005
Threadgill1 metabolic panel
with acetaminophen
Blood urea nitrogen, alanine transaminase, aspartate transaminase (serum), liver enzyme homeostasis. Acetaminophen (several doses) vs. control, several timepoints post-Rx. 18h fast. inbred w/CC7   (37) m 8-17wks 2005
Threadgill1 metabolite quantification
with acetaminophen
Liver protein homeostasis. Acetaminophen vs. control. 18h fast. inbred w/CC7   (37) m 8-17wks 2005
Threadgill1 organ weights
with acetaminophen
Liver weight after acetaminophen (several doses) vs. control. 18h fast. inbred w/CC7   (37) m 8-17wks 2005
Tomasini1 biomarker quantification Fibronectin. inbred   (25) both 9wks 2007
Tordoff1 body weight Body weight during testing. inbred   (28) m 9wks 2001
Tordoff1 bottle choice test Various salt solutions (several concentrations) vs. water. inbred   (28) m 9wks 2001
Tordoff2 body weight Body weight inbred   (28) m 4-12wks 2001
Tordoff2 intake monitoring Food intake, water intake. Daily. inbred   (28) m 4-12wks 2001
Tordoff3 body weight Body weight inbred w/CC7   (40) both 9-15wks 2002
Tordoff3 bottle choice test Various salt solutions (several concentrations) vs. water. inbred w/CC7   (40) both 9-15wks 2002
Tordoff3 DXA Body mass, fat mass, lean mass, bone mineral density and content. inbred w/CC7   (40) both 9-15wks 2002
Tordoff3 metabolic panel Ionized and total blood calcium, blood pH. inbred w/CC7   (40) both 9-15wks 2002
Tordoff3 monitoring system Bleeding time to collect approx 30 µL. inbred w/CC7   (40) both 9-15wks 2002
UCLA1 genotyping SNP profiling, 132,000+ genomic locations, 1-19,X HMDP   (248) both 2018
Vulpe1 mineral quantification Liver mineral levels. Iron, copper, zinc. Iron homeostasis. inbred   (18) both 8wks 2010
Vulpe1 transferrin quantification Diferric transferrin (plasma). inbred   (18) both 8wks 2010
Wahlsten1 elevated plus maze Locomotor, exploratory, and anxiety-related behavior. inbred   (21) both 9, 12 wks 2003
Wahlsten1 histopathology Corpus callosum, hippocampus, anterior commisure. inbred   (21) both 9, 12 wks 2003
Wahlsten1 open field test Locomotor, exploratory, and anxiety-related behavior. 5 min test. inbred   (21) both 9, 12 wks 2003
Wahlsten1 organ weights Brain weight. inbred   (21) both 9, 12 wks 2003
Wahlsten2 behavior observation Wildness scoring during various phenotyping tests. inbred   (21) both 10-12wks 2003
Willott1 acoustic startle test Acoustic startle response, prepulse inhibition. inbred w/CC7   (40) both 5-6wks 2002
Willott1 body weight Body weight inbred w/CC7   (40) both 5-6wks 2002
Wiltshire1 elevated plus maze Locomotor activity. inbred   (38) both 12-14wks 2010
Wiltshire1 light-dark box Light-dark test. Anxiety-related behavior. inbred   (38) both 12-14wks 2010
Wiltshire1 open field test Locomotor activity. inbred   (38) both 12-14wks 2010
Wiltshire2 drug and metabolite quantification
with fluoxetine
Fluoxetine and norfluoxetine concentration (serum) after fluoxetine. inbred   (30) m 9-11wks 2011
Wiltshire2 open field test
with fluoxetine
Locomotor activity, exploratory and anxiety-related behavior. Fluoxetine-treated vs. control. 7 min test. inbred   (30) m 9-11wks 2011
Wiltshire2 tail suspension test
with fluoxetine
Immobility. Fluoxetine-treated vs. control. 5 min test. inbred   (30) m 9-11wks 2011
Wiltshire3 biomarker quantification
with fluoxetine
Brain tissue survey of 30 biochemical analytes. Fluoxetine-treated vs. control. 21d. inbred   (30) m 10-11wks 2011
Wiltshire4 immune cell quantification
with cancer drugs
In vitro study of 4 cancer chemotherapies (BEZ235, doxorubicin, idarubicin, selumetinib) vs. control. Effect on immune cells. Normalized data. inbred w/CC7   (36) m 10wks 2015
Xing1 ECG Heart rate and wave intervals. Conscious. Aging study, 6mo, 12mo, 20mo. inbred   (29) both 26, 52, 87 wks 2008
Xing2 gait analysis Aging study, 6mo, 12mo, 18mo. inbred   (31) both 26, 52, 78 wks 2010
Yuan1 body weight Aging study, 6mo, 12mo, and 18mo. inbred   (33) both 26, 52, 78 wks 2007
Yuan1 hormone quantification Insulin-like growth factor 1 (serum). Aging study, 6mo, 12mo, and 18mo. inbred   (33) both 26, 52, 78 wks 2007
Yuan2 colony observation Life span study. Survival curves. Aging study. inbred   (31) both max lifespan 2007
Yuan3 lipid profile Cholesterol (HDL). Aging study, 6mo, 12mo, 18mo. 4h fast, plasma. inbred   (32) both 26, 52, 78 wks 2008
Yuan3 metabolic panel Clinical blood chemistry. Aging study, 6mo, 12mo, 18mo. inbred   (32) both 26, 52, 78 wks 2008
Yuan4 colony observation Observed age at vaginal opening (patency). Aging study. inbred   (33) f 2-9wks 2009
Zheng1 tympanometry Middle ear function. inbred   (61) both 15-51d 2008